Kwality Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
875.00 +2.55 (0.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
830
Today’s High
895
52 Week Low
340
52 Week High
961.15
Key Metrics
- Market Cap (In Cr) 905.27
- Beta 0.97
- Div. Yield (%) 0
- P/B 4.04
- TTM P/E 27.93
- Peg Ratio 1.92
- Sector P/E 32.87
- D/E 0.43
- Open Price 895
- Prev Close 872.45
Kwality Pharmaceuticals Analysis
Price Analysis
-
1 Week0.43%
-
3 Months25.71%
-
6 Month71.93%
-
YTD118.22%
-
1 Year124.37%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Kwality Pharmaceuticals News
Kwality Pharmaceuticals Q3 FY24 Results Live: Profit Rise by 7% YoY
1 min read . 09 Feb 2024Ashish Kacholia portfolio: Multibagger stock gives 600% return in one year
1 min read . 26 Apr 2022Kwality Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 307.17
- Selling/ General/ Admin Expenses Total
- 32.56
- Depreciation/ Amortization
- 19.56
- Other Operating Expenses Total
- 55.11
- Total Operating Expense
- 267.52
- Operating Income
- 39.66
- Net Income Before Taxes
- 31.1
- Net Income
- 23.8
- Diluted Normalized EPS
- 27.92
- Period
- 2024
- Total Assets
- 394.21
- Total Liabilities
- 170
- Total Equity
- 224.21
- Tangible Book Valueper Share Common Eq
- 216.08
- Period
- 2024
- Cashfrom Operating Activities
- 42.98
- Cashfrom Investing Activities
- -26.4
- Cashfrom Financing Activities
- -17.4
- Net Changein Cash
- -0.81
- Period
- 2023
- Total Revenue
- 251.03
- Selling/ General/ Admin Expenses Total
- 29.96
- Depreciation/ Amortization
- 14.96
- Other Operating Expenses Total
- 50.86
- Total Operating Expense
- 222.38
- Operating Income
- 28.65
- Net Income Before Taxes
- 25.57
- Net Income
- 19.37
- Diluted Normalized EPS
- 30.64
- Period
- 2023
- Total Assets
- 353.63
- Total Liabilities
- 153.12
- Total Equity
- 200.52
- Tangible Book Valueper Share Common Eq
- 193.25
- Period
- 2023
- Cashfrom Operating Activities
- 41.38
- Cashfrom Investing Activities
- -48.44
- Cashfrom Financing Activities
- 0.99
- Net Changein Cash
- -6.06
- Period
- 2022
- Total Revenue
- 456.19
- Selling/ General/ Admin Expenses Total
- 20.15
- Depreciation/ Amortization
- 10.69
- Other Operating Expenses Total
- 63.77
- Total Operating Expense
- 295.21
- Operating Income
- 160.97
- Net Income Before Taxes
- 161.57
- Net Income
- 119.99
- Diluted Normalized EPS
- 115.64
- Period
- 2022
- Total Assets
- 340.59
- Total Liabilities
- 159.45
- Total Equity
- 181.14
- Tangible Book Valueper Share Common Eq
- 174.58
- Period
- 2022
- Cashfrom Operating Activities
- 60.6
- Cashfrom Investing Activities
- -62.93
- Cashfrom Financing Activities
- 5.66
- Net Changein Cash
- 3.33
- Period
- 2021
- Total Revenue
- 262.01
- Selling/ General/ Admin Expenses Total
- 15.9
- Depreciation/ Amortization
- 6.49
- Other Operating Expenses Total
- 51.67
- Total Operating Expense
- 239.66
- Operating Income
- 22.36
- Net Income Before Taxes
- 21.27
- Net Income
- 15.15
- Diluted Normalized EPS
- 14.6
- Period
- 2021
- Total Assets
- 166.26
- Total Liabilities
- 105.11
- Total Equity
- 61.15
- Tangible Book Valueper Share Common Eq
- 58.94
- Period
- 2021
- Cashfrom Operating Activities
- 26.71
- Cashfrom Investing Activities
- -23.2
- Cashfrom Financing Activities
- 0.77
- Net Changein Cash
- 4.27
- Period
- 2020
- Total Revenue
- 139.3
- Selling/ General/ Admin Expenses Total
- 11.93
- Depreciation/ Amortization
- 4.43
- Other Operating Expenses Total
- 26.1
- Total Operating Expense
- 129.54
- Operating Income
- 9.76
- Net Income Before Taxes
- 10.92
- Net Income
- 8.32
- Diluted Normalized EPS
- 8.02
- Period
- 2020
- Total Assets
- 132.69
- Total Liabilities
- 86.69
- Total Equity
- 46.01
- Tangible Book Valueper Share Common Eq
- 44.34
- Period
- 2020
- Cashfrom Operating Activities
- 6.16
- Cashfrom Investing Activities
- -17.8
- Cashfrom Financing Activities
- 11.77
- Net Changein Cash
- 0.14
- Period
- 2019
- Total Revenue
- 166.29
- Selling/ General/ Admin Expenses Total
- 8.56
- Depreciation/ Amortization
- 3.12
- Other Operating Expenses Total
- 22.58
- Total Operating Expense
- 153.71
- Operating Income
- 12.59
- Net Income Before Taxes
- 10.91
- Net Income
- 7.55
- Diluted Normalized EPS
- 7.28
- Period
- 2019
- Total Assets
- 105.38
- Total Liabilities
- 68.08
- Total Equity
- 37.3
- Tangible Book Valueper Share Common Eq
- 35.95
- Period
- 2019
- Cashfrom Operating Activities
- 13.58
- Cashfrom Investing Activities
- -11.78
- Cashfrom Financing Activities
- -2
- Net Changein Cash
- -0.21
- Period
- 2018
- Total Revenue
- 137.49
- Selling/ General/ Admin Expenses Total
- 5.61
- Depreciation/ Amortization
- 2.98
- Other Operating Expenses Total
- 18.93
- Total Operating Expense
- 128.81
- Operating Income
- 8.68
- Net Income Before Taxes
- 7.3
- Net Income
- 4.55
- Diluted Normalized EPS
- 4.37
- Period
- 2018
- Total Assets
- 96.2
- Total Liabilities
- 66.45
- Total Equity
- 29.75
- Tangible Book Valueper Share Common Eq
- 28.67
- Period
- 2018
- Cashfrom Operating Activities
- -0.57
- Cashfrom Investing Activities
- -6.2
- Cashfrom Financing Activities
- 5.39
- Net Changein Cash
- -1.38
- Period
- 2024-09-30
- Total Revenue
- 90.03
- Selling/ General/ Admin Expenses Total
- 10.31
- Depreciation/ Amortization
- 4.62
- Other Operating Expenses Total
- 16.12
- Total Operating Expense
- 75
- Operating Income
- 15.04
- Net Income Before Taxes
- 12.55
- Net Income
- 8.47
- Diluted Normalized EPS
- 8.15
- Period
- 2024-09-30
- Total Assets
- 393.5
- Total Liabilities
- 152.46
- Total Equity
- 241.03
- Tangible Book Valueper Share Common Eq
- 232.3
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 17.39
- Cashfrom Investing Activities
- -7.52
- Cashfrom Financing Activities
- -9.03
- Net Changein Cash
- 0.84
- Period
- 2024-06-30
- Total Revenue
- 80.08
- Selling/ General/ Admin Expenses Total
- 9.73
- Depreciation/ Amortization
- 4.02
- Other Operating Expenses Total
- 13.99
- Total Operating Expense
- 66.76
- Operating Income
- 13.32
- Net Income Before Taxes
- 11.12
- Net Income
- 8.36
- Diluted Normalized EPS
- 8.04
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 91.98
- Selling/ General/ Admin Expenses Total
- 9
- Depreciation/ Amortization
- 5.07
- Other Operating Expenses Total
- 16.32
- Total Operating Expense
- 83.52
- Operating Income
- 8.46
- Net Income Before Taxes
- 5.98
- Net Income
- 4.36
- Diluted Normalized EPS
- 8.78
- Period
- 2024-03-31
- Total Assets
- 394.21
- Total Liabilities
- 170
- Total Equity
- 224.21
- Tangible Book Valueper Share Common Eq
- 216.08
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 42.98
- Cashfrom Investing Activities
- -26.4
- Cashfrom Financing Activities
- -17.4
- Net Changein Cash
- -0.81
- Period
- 2023-12-31
- Total Revenue
- 78.1
- Selling/ General/ Admin Expenses Total
- 8.01
- Depreciation/ Amortization
- 4.82
- Other Operating Expenses Total
- 13.45
- Total Operating Expense
- 66.23
- Operating Income
- 11.87
- Net Income Before Taxes
- 9.75
- Net Income
- 7.69
- Diluted Normalized EPS
- 7.39
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 69.65
- Selling/ General/ Admin Expenses Total
- 7.92
- Depreciation/ Amortization
- 4.88
- Other Operating Expenses Total
- 12.34
- Total Operating Expense
- 59.3
- Operating Income
- 10.35
- Net Income Before Taxes
- 8.17
- Net Income
- 6.24
- Diluted Normalized EPS
- 5.99
- Period
- 2023-09-30
- Total Assets
- 354.9
- Total Liabilities
- 142.85
- Total Equity
- 212.06
- Tangible Book Valueper Share Common Eq
- 204.37
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 21.21
- Cashfrom Investing Activities
- -13.31
- Cashfrom Financing Activities
- -8.07
- Net Changein Cash
- -0.17
- Period
- 2023-06-30
- Total Revenue
- 67.45
- Selling/ General/ Admin Expenses Total
- 7.63
- Depreciation/ Amortization
- 4.79
- Other Operating Expenses Total
- 12.99
- Total Operating Expense
- 58.47
- Operating Income
- 8.98
- Net Income Before Taxes
- 7.2
- Net Income
- 5.42
- Diluted Normalized EPS
- 5.1
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 68.8
- Selling/ General/ Admin Expenses Total
- 7.88
- Depreciation/ Amortization
- 4.43
- Other Operating Expenses Total
- 14.76
- Total Operating Expense
- 78.28
- Operating Income
- -9.47
- Net Income Before Taxes
- -9.68
- Net Income
- -7.38
- Diluted Normalized EPS
- 3.4
- Period
- 2023-03-31
- Total Assets
- 353.63
- Total Liabilities
- 153.12
- Total Equity
- 200.52
- Tangible Book Valueper Share Common Eq
- 193.25
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 41.38
- Cashfrom Investing Activities
- -48.44
- Cashfrom Financing Activities
- 0.99
- Net Changein Cash
- -6.06
- Period
- 2022-12-31
- Total Revenue
- 56.2
- Selling/ General/ Admin Expenses Total
- 8.05
- Depreciation/ Amortization
- 3.55
- Other Operating Expenses Total
- 12.31
- Total Operating Expense
- 44.66
- Operating Income
- 11.54
- Net Income Before Taxes
- 9.95
- Net Income
- 7.19
- Diluted Normalized EPS
- 6.82
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Kwality Pharmaceuticals Technical
Moving Average
SMA
- 5 Day880.65
- 10 Day890.22
- 20 Day873.87
- 50 Day824.57
- 100 Day708.94
- 300 Day598.87
Kwality Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Anuh Pharma
- 194.9
- 5.45
- 2.88
- 265
- 140.1
- 976.68
- Fermenbio
- 326.15
- -0.7
- -0.21
- 354.6
- 145
- 941.73
- Kwality Pharmaceuticals
- 875
- 2.55
- 0.29
- 961.15
- 340
- 907.92
- Shree Ganesh Remedies
- 669
- -1.35
- -0.2
- 950.05
- 557.95
- 859.48
- Nectar Lifesciences
- 34
- -0.2
- -0.58
- 56.39
- 25.02
- 762.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Anuh Pharma
- 16.42
- 3.39
- 16.37
- 7.06
- Fermenbio
- -
- 3.31
- 1.52
- 1.05
- Kwality Pharmaceuticals
- 30.96
- 4.03
- 30.12
- 13.13
- Shree Ganesh Remedies
- 31.28
- 7.35
- 24.29
- 19.73
- Nectar Lifesciences
- 157.05
- 0.73
- -0.65
- -0.41
Kwality Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-Oct-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results
- 06-Feb-24
- Quarterly Results
- 04-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 27-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- 13-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 24-Sept-24
- 06-Sept-24
- AGM
- 30-Sept-23
- 07-Sept-23
- AGM
- 30-Sept-22
- 06-Sept-22
- AGM